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Plasma adenosine levels are elevated in cardiovascular disease including hypertension and heart failure and the nucleoside has been proposed to serve as an endogenous anti-myocardial remodelling factor. We studied the modulation of phenylephrine-induced hypertrophy by adenosine receptor activation in isolated neonatal cultured ventricular myocytes. Phenylephrine (10 µ M) increased cell size by 35% and significantly increased expression of atrial natriuretic peptide. These effects were reduced by the stable adenosine analogue 2-chloro adenosine and completely blocked by the adenosine A 1 receptor agonist CPA (1 µ M) , the A 2A receptor agonist CGS21680 (100 nM) and the A 3 receptor agonist IB-MECA (100 nM). The antihypertrophic effects of all three agonists were completely reversed by their respective antagonists.
Phenylephrine significantly upregulated expression of the immediate early gene c-fos especially within the first 30 min of phenylephrine treatment. These effects were almost completely inhibited by all adenosine receptor agonists. Although phenylephrine also induced early stimulation of both p38MAPK and ERK, these responses were unaffected by adenosine agonists.
The expression of the G-protein regulatory factors RGS2 and RGS4 were increased by nearly three-fold fold by phenylephrine treatment although this was completely prevented by adenosine receptor agonists. These agents also blocked the ability of phenylephrine to upregulate Na-H exchange isoform 1 (NHE1) expression in hypertrophied myocytes. Thus, our results demonstrate an antihypertrophic effect of adenosine acting via multiple receptor subtypes through a mechanism involving downregulation of NHE1 expression. The ability to prevent RGS upregulation further suggests that adenosine receptor activation minimizes signalling which leads to hypertrophic responses.
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Introduction
Adenosine, a product of adenine nucleotide catabolism, has been demonstrated to exert numerous effects on the cardiovascular system. For example, the vasodilating property of adenosine is well-established and it has been proposed that adenosine is an important regulator of coronary vascular resistance particularly under hypoxic situations; a phenomenon termed the "Berne hypothesis." Extensive evidence has been presented demonstrating a cardioprotective effect of adenosine, as well as adenosine analogues, against ischemic and reperfusion injury using a variety of both in vitro and in vivo approaches (reviewed in Headrick et al., 2003) which may be due, at least in part, to inhibition of the deleterious effects of oxidative stress on the heart (Karmazyn and Cook, 1992) .
There is emerging evidence that adenosine could represent an important regulator of the myocardial remodelling process in response to various stimuli. Plasma adenosine levels are elevated in experimental hypertension (Ohnishi et al., 1988; Yamada et al., 1992) and elevated plasma concentrations of the nucleoside have been demonstrated in patients with congestive heart failure irrespective of causative factor (Funaya et al., 1997) . With respect to the latter, the degree of elevation in plasma adenosine concentrations was dependent on the severity of heart failure according to New York Heart Association [NYHA] classification with the greatest increases [more than 5 fold] observed in NYHA class IV patients (Funaya et al., 1997) . A study from the same group also demonstrated that administration of nucleoside transport inhibitors dipyridamole and dilazep (which increase adenosine levels) for 6 months reduced the severity of heart failure with an improvement in both ejection fraction and maximal oxygen consumption
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with the beneficial effects reversing after drug discontinuation (Kitakaze et al., 1998) . Elevated levels of adenosine in cardiovascular disease may therefore represent a protective mechanism, for example elevated adenosine could counter the deleterious effects of sympathetic nervous stimulation by its well-known direct vasodilating effect or by inhibition of neurotransmitter release. Adenosine could further exert antihypertensive effects by blocking the renin angiotensin system (Ohnishi et al., 1988) . In rats with pressure overloaded hypertrophy the adenosine uptake blocker dipyridamole reduced abnormal left ventricular chamber filling and preserved adrenergic responsiveness in pressure overload-induced hypertrophy (Chung et al., 1998) .
Extensive studies on the potential direct effects of adenosine on the remodelling process have not been carried out particularly in terms of understanding mechanisms. In the present report, we used neonatal cultured rat ventricular myocytes to assess the effect of adenosine, and more specifically, selective adenosine receptor agonists on hypertrophy induced by the α 1 adrenoceptor agonist phenylephrine.

Methods
Cell Cultures
Primary myocyte cultures were prepared from neonatal Harlan Sprague-Dawley rat heart ventricles as described previously (Karmazyn et al., 2003) . Isolated primary myocytes were plated onto glass coverslips for physiologic studies, or onto Primaria TM (Falcon) culture dishes or flasks for collection of cell extracts. Myocytes were maintained for 48 h in medium containing Dulbecco's modified Eagle medium/Ham's F-12 supplemented with 10% fetal bovine serum, 10 µ g/ml transferrin, 10 µ g/ml insulin, 10 ng/ml selenium, 50 units/ml penicillin, 50 µ g/ml streptomycin, 2 mg/ml bovine serum albumin, 5 µ g/ml linoleic acid, 3 mM pyruvic acid, 0.1 mM minimum essential medium non-essential amino acids, 10% minimal essential medium (MEM) vitamin solution, 0.1 mM bromodeoxyuridine, 100 µ M L-ascorbic acid, and 30 mM HEPES, pH 7.2.
Experimental Protocol
Cells were serum-starved 24 h prior to all experiments after which cells were treated for 24 hours with 10 µ M phenylephrine. To assess the effect of adenosine in modulating hypertrophic responses we first determined the effect of the stable adenosine analogue, 2Cl-adenosine (10 µ M). The effect of phenylephrine was subsequently studied in the presence of the following adenosine receptor selective agonists: the A 1 receptor agonist N 6 cyclopentyl adenosine (CPA 1 µ M), the A 2A receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5'-Nethylcarboxamidoadenosine (CGS 21680, 100 nM) and the A 3 receptor agonist N 9 JPET #73122 their corresponding antagonists, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 10 µ M), 8-(3-chlorostyryl) caffeine CSC (10 µ M)) and 3-propyl-6-ethyl-
respectively was determined. The concentrations of drugs used in the present study reflect those which were found to exert maximal effects in initial experiments aimed at identifying optimal concentrations of each agent. To confirm selectivity of the effects of antagonist against their respective receptors, experiments were performed in which the effect of the specific receptor antagonist was also tested against agonists acting on either of the other two receptors. For all experiments, 2Cl-adenosine, adenosine receptor agonists or the agonist-antagonist combination was added 10 minutes before administration of phenylephrine.
Measurement of Cell Surface Area
Cardiomyocyte surface area was determined for 50 randomly selected cells per experiment and averaged to provide an N value of one. Cells were visualized with a Leica inverted microscope equipped with a Polaroid digital camera using 20x magnification. Cell area was determined using Mocha software. with a PCR product of 320 bp. Samples were then electrophoresed in 3 % agarose gels containing ethidium bromide and quantified via computer densitometry. GAPDH was used as the reference gene for ANP expression whereas for NHE1 expression the gene product was standardized using competitive PCR where NHE1 mRNA expression was compared to amplification of competitor fragments. For GAPDH the forward and reverse primers were 5'-AAAGGGCATCCTGGGCTACA-3' and 5'-CAGTGTTGGGGGCTGAGTTG-3', respectively.
Determination of Gene Expression
Real time PCR was used to assess mRNA expression of c-fos and RGS using a DNA Engine 
Western Blotting for p38MAPK, ERK and NHE-1
The cells were plated at a concentration of 6 x 10 6 cells/ 6 cm dish. After washing with PBS two times, the cells were scraped into 100 µ l lysis buffer (20 mM Tris, 150 mM NaCl, 1% Triton-X 100, 10% glycerol, 2 mM EDTA, 2mM EGTA, 50 mM NaF, 200 µ M Na 3 VO 4 , 10 mM Na 4 P 2 O 7 , 40 mM β -glycerophosphate, 10 µ g/ml leupeptin, 1 µ M pepstatin A, 1 mM PMSF, and centrifuged
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at 10000 x g for 5 min at 4 0 C. The supernatant was transferred to a fresh tube. The protein concentration was assayed by Bradford protein assay kit (Bio-Rad). 30 µ g protein were loaded in 10% SDS-PAGE, and transferred to nylon membrane (Amersham). The membranes were blocked in 5% dry milk for 3 hours, primary antibody for 2h, secondary antibody for 1h, and then detected by ECL reagent (Amersham). Antibodies were purchased from Cell Signaling and used at 1:500, 1:1000 and 1:2000 dilutions for NHE-1, p38MAPK and ERK, respectively .
Statistical Analysis
Results are given as means ± SEM. Statistical analyses were performed by using one-way analysis of variance (ANOVA). The post-test comparison was performed by the method of Bonferroni. Differences were considered significant when P<0.05. phenylephrine-induced hypertrophy (n=6 for all groups). Phenylephrine on its own increased cells size by 39 ± 7% which was inhibited by the A1 receptor agonist CPA alone (5 ± 2% increase), or in the presence of the A 2A antagonist CSC (13 ± 2%) or the A3 antagonist MRS (9 ± 2%). Similarly, the effect of the A 2A
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agonist CGS 21680 was also unaffected by the A1 receptor antagonist DPCPX (9 ± 3%) or the A3 antagonist MRS (4 ±1%). Finally, in the last set of studies the effect of the A3 agonist was unaffected by either DPCPX (7 ± 2%) or CSC (8 ± 3%). Thus, although a slight attenuation of the antihypertophic effect of CPA was observed with CSC, the results confirm the relative selectivity of adenosine receptor antagonists against their specific receptor subtypes.
The ability of adenosine receptor agonists to activate MAP kinase was next determined by studying the early phosphorylation of p38MAPK and p44/42 (ERK). Phenylephrine increased ERK phosphorylation with peak values attained by 5 and 15 minutes after drug addition ( Figure 6 ) However, there was generally no effect of any of the adenosine receptor agonists. Virtually identical results were observed with respect to p38MAPK ( Figure 7 ). MAP kinase activities in cells treated for longer than 60 minutes were identical to basal values and unaffected by any treatment (not shown). Increased proto-oncogene expression has also been implicated in the development of cardiomyocyte hypertrophy and we therefore determined mRNA expression of c-fos after phenylephrine addition in the absence or presence adenosine receptor agonists. As shown in Figure 8 phenylephrine produced a rapid c-fos induction during the initial 30 min of phenylephrine treatment, however this was significantly attenuated by all adenosine receptor agonists.
Recent evidence suggests the involvement of NHE1 in cardiomyocyte hypertrophy as well as an ability of adenosine to inhibit phenylephrine stimulated NHE1 activation in cardiomyocytes, through an A 1 receptor mechanism. Accordingly, we studied the relationship between NHE1 14 expression and the antihypertrophic effects of adenosine receptor antagonists. As Figure 9 JPET #73122 illustrates, 24 hr exposure to phenylephrine increased cardiomycyte NHE1 expression, however, this was completely prevented by adenosine receptor activation, the latter effect being reversed in the presence of the receptor antagonist. Moreover, using Western blotting we observed that NHE-1 protein abundance was increased by 37 ± 3.8 % by phenylephrine alone (P<0.05 from control) whereas in the presence of either CPA, CGS21680 or IB-MECA the effects of phenylephrine were reduced to 3.8 ± 0.53%, 6.2 ± .86% and 13 ± 3.8% (P>0.05, n=5 for all groups).
Phenylephrine also increased the expression of both RGS2 and RGS4, which are important in regulating Gq-dependent processes, by nearly three-fold although these effects were completely abrogated by all three adenosine receptor agonists as well as 2Cl-adenosine ( Figure   10 ). This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
We studied the effect of adenosine receptor modulators on the hypertrophic effect of the α 1 adrenoceptor agonist phenylephrine, an agent which has been used extensively to initiate hypertrophy in cultured myocytes. 2Cl-adenosine, the non selective adenosine receptor agonist which is not subjected to extensive hydrolysis by adenosine deaminase as is the parent nucleoside, effectively inhibited the hypertrophy produced by phenylephrine although the effect was generally less than that produced by individual receptor agonists alone. Although speculative, perhaps this reflects a non-specific effect of the nucleoside or some degree of either hydrolysis or cellular uptake of 2Cl-adenosine by the nucleoside transporter thereby limiting its efficacy.
We then studied the effect of agonists acting on the A 1 , A 2A and A 3 receptors on their ability to modulate the phenylephrine induced hypertrophy. These receptor agonists were selected based on our ability to identify the abundant presence of these receptor subtypes using Western blotting whereas only faint A 2B receptor blots were seen (not shown). Moreover, the present lack of availability of highly selective A 2B receptor ligands led us to concentrate our studies on the other three receptor subtypes. It was surprising that the antihypertrophic effects of adenosine receptor agonists were similarly observed with agents acting on the A 1 , A 2A and A 3 receptors in relatively equal fashion. Nonetheless, despite the fact that these receptors are coupled to diverse cell signalling processes activators of multiple adenosine receptor subtypes have also been
shown to protect the ischemic and reperfused myocardium (Yao and Gross 1993; Auchampach et al., 2004; Boucher et al., 2004) . In the present study, the antihypertrophic effect of adenosine antagonists were restricted to their respective agonists suggesting a high degree of selectivity.
We also used identical pharmacological tools to probe the adenosine system such that differences in agents used could not account for the differences in responses seen in the two studies although the concentration of phenylephrine in our study was 10 fold lower than that ). However, in that study these effects were found to be exclusively dependent on adenosine A 2B receptor activation with no effect of either an A1 or an A 2A receptor agonists (Dubey et al., 2001 ). Thus, the exact nature of the receptors mediating the antihypertrophic or antiremodelling effect of adenosine requires further studies.
Our study was also designed to explore the potential mechanisms underlying the antihypertrophic effect of adenosine. As previously suggested (Kitakaze and Hori, 2000) there are a number of potential mechanisms by which adenosine could exert salutary effects in heart failure such as attenuation of norepinephrine release or decreased endothelin, angiotensin II or cytokine production. Moreover, collagen and protein synthesis by isolated cardiac fibroblasts is inhibited by adenosine suggesting that adenosine has an antifibrosis effect (Dubey et al., 2001 ). Lastly, it should be emphasized that in our study the antihypertrophic effect of adenosine or adenosine receptor agonists was restricted to determining their effects against phenylephrine and it remains to be determined whether the effect we report with multiple adenosine receptor agonists can also be applied to other hypertrophic stimuli or to the in vivo situation.
We also examined NHE1 expression for a number of reasons. For example, there is now strong evidence which suggests an important role for this transporter in mediating cardiac hypertrophy (Cingolani, 1999; Karmazyn, 2001) . Secondly, there is also evidence that adenosine inhibits α 1 adrenergic-mediated activation of NHE1 in cardiac cells through a mechanism mediated by A 1 receptors (Avkiran and Yokoyama, 2000) . herein in response to the α 1 adrenoceptor activation may be related to these effects although this needs to be determined with further experiments. It is interesting that although RGS proteins appear to be antihypertrophic, overexpression of RGS4 in transgenic mice has been shown to enhance mortality following left ventricular pressure overload produced by aortic coarctation possibly due to reduced cardiac compensation (Rogers et al., 1999) . The mechanism(s) via which adenosine receptor agonists attenuate RGS protein upregulation is at present unclear. We have previously demonstrated that adenosine A 1 receptor activation inhibits phenylephrineinduced cardiomyocyte changes including the increase in the calcium transient, however no effect was seen with either an A 2A or A 3 agonist (Hoque et al., 2000) . Cardiomyocyte adenosine receptors are not known to decrease phospholipase C activity and indeed some adenosine receptor subtypes are linked to PKC activation (Henry et al., 1996) . Intriguingly, one study has shown RGS2 to be increased in human heart failure and that symptomatic relief resulting from using a left ventricular assist device (LVAD) was accompanied by a decrease in this protein back to levels observed in nonfailing hearts (Takeishi et al., 2000) . It is interesting that the use of LVAD has been shown to reverse left ventricular hypertrophy (Zafeiridis et al., 1998) . While 
